Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 19/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 12/20 | 0.75 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20524109 | 0.86 | HDAC6 (1.00) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL21840273 | 0.83 | HDAC6 (0.71) | HDAC6HDAC1MEN1NPC1RAB9A | |
| SCHEMBL20524103 | 0.82 | HDAC6 (0.69) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL20524164 | 0.76 | HDAC6 (1.00) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL21840274 | 0.74 | HDAC6 (0.80) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL31163420 | 0.73 | HDAC6 (0.57) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL20524131 | 0.72 | HDAC6 (1.00) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL20524091 | 0.71 | HDAC6 (0.59) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL20524059 | 0.69 | HDAC6 (0.78) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL27295996 | 0.68 | HDAC6 (0.52) | HDAC6HDAC3MEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024493-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-07-02 | — | — | US | claimed |
| US-11472780-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY (US) | 2022-10-18 | — | — | US | claimed |
| US-20220153709-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2022-05-19 | — | — | US | claimed |
| US-20200115350-A1 | Isoxazole Hydroxamic Acids As Histone Deacetylase 6 Inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION | 2020-04-16 | — | — | US | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | disclosed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | disclosed |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-10-17 | — | — | US | disclosed |
| US-12024493-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-07-02 | — | — | US | disclosed |
| US-12024493-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-07-02 | — | — | US | disclosed |
| US-12024493-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230391868-A1 | COMPOSITIONS FOR AND METHODS OF TREATING CANCER | THE GEORGE WASHINGTON UNIVERSITY | 2023-12-07 | — | — | US | disclosed |
| US-20220401474-A1 | HDAC6-ACTIVATED MACROPHAGES, COMPOSITIONS, AND USES THEREOF | MEDSTAR HEALTH | 2022-12-22 | — | — | US | disclosed |
| US-11472780-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY (US) | 2022-10-18 | — | — | US | disclosed |
| US-20220153709-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2022-05-19 | — | — | US | disclosed |
| US-20220153709-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2022-05-19 | — | — | US | disclosed |
| WO-2022094319-A1 | STAT-ACTIVATED MACROPHAGES, COMPOSITIONS, AND USES THEREOF | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2022-05-05 | — | — | WO | disclosed |
| US-20200115350-A1 | Isoxazole Hydroxamic Acids As Histone Deacetylase 6 Inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION | 2020-04-16 | — | — | US | disclosed |
| US-20200115350-A1 | Isoxazole Hydroxamic Acids As Histone Deacetylase 6 Inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION | 2020-04-16 | — | — | US | disclosed |
| EP-3600295-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | The George Washington University, A Congressionally Chartered Not-For-Profit Corporation (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018183701-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY (US) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | HDAC3, HDAC1, HDAC4 | HDAC6 10/4885HDAC1 2/4885HDAC8 9/4885 |
| US-20220153709-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | HDAC1, HDAC7, HDAC5 | HDAC6 10/4885HDAC1 1/4885HDAC8 6/4885 |
| US-20220401474-A1 | HDAC6-ACTIVATED MACROPHAGES, COMPOSITIONS, AND USES THEREOF | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885HDAC1 2/4885HDAC8 6/4885 |
| US-11472780-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | HDAC1, HDAC7, HDAC5 | HDAC6 10/4885HDAC1 1/4885HDAC8 6/4885 |
| US-20230391868-A1 | COMPOSITIONS FOR AND METHODS OF TREATING CANCER | CD47, HDAC6, HDAC3 | HDAC6 2/4885HDAC1 4/4885HDAC8 12/4885 |
| US-12024493-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | HDAC1, HDAC7, HDAC5 | HDAC6 10/4885HDAC1 1/4885HDAC8 6/4885 |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | HDAC1, HDAC7, HDAC5 | HDAC6 10/4885HDAC1 1/4885HDAC8 6/4885 |
| US-20200115350-A1 | Isoxazole Hydroxamic Acids As Histone Deacetylase 6 Inhibitors | HDAC1, HDAC7, HDAC5 | HDAC6 10/4885HDAC1 1/4885HDAC8 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.